Oxford Biomedica (LON: OXB) revenue
Oxford Biomedica reported revenue of £168.7m for fiscal 2025, 31.0% more than in fiscal 2024 (£128.8m). Since fiscal 2021 its revenue has grown by 18.2%, an average growth of 4.3% a year.
Oxford Biomedica has grown its revenue for 2 years in a row, and fiscal 2025 is the highest of its 5 fiscal years on record. The biggest drop was in fiscal 2023, −36.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | £168.7m | +31.0% | −£22.5m | −13.3% |
| 2024 | £128.8m | +43.8% | −£39.4m | −30.6% |
| 2023 | £89.5m | −36.0% | −£184.2m | −205.7% |
| 2022 | £140.0m | −2.0% | −£30.2m | −21.6% |
| 2021 | £142.8m | — | £20.8m | 14.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of pounds, except per-share amounts.
Oxford Biomedica revenue compared with its sector
By revenue for its latest fiscal year, Oxford Biomedica ranks 43rd of the 59 Spanish and European health care companies with a page on Celsmar. The sector median grew 4.5% in its latest fiscal year; Oxford Biomedica, 31.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 41st | Lumibird | €225.6m | 8.9% |
| 42nd | PharmaMar | €221.4m | 26.6% |
| 43rd | Oxford Biomedica | £168.7m | 31.0% |
| 44th | Valneva | €174.7m | 3.0% |
| 45th | Atrys Health | €141.0m | 8.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in health care stocks.
Questions about the revenue of Oxford Biomedica
- How much revenue did Oxford Biomedica make in fiscal 2025?
- Oxford Biomedica reported revenue of £168.7m for fiscal 2025, compared with £128.8m in fiscal 2024.
- How much has the revenue of Oxford Biomedica grown?
- Between fiscal 2021 and fiscal 2025 it went from £142.8m to £168.7m: 18.2% more, an average growth of 4.3% a year.
- What was the best year for revenue at Oxford Biomedica?
- Of its last 5 fiscal years, fiscal 2025, with £168.7m.
- Where does Oxford Biomedica rank in its sector by revenue?
- It ranks 43rd of the 59 Spanish and European health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Oxford Biomedica come from?
- From the report Oxford Biomedica files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
From the annual report Oxford Biomedica files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Oxford Biomedica: the Oxford Biomedica page · annual accounts · net income.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.